杏林製薬の株価時系列
| 日付 | 始値 | 高値 | 安値 | 終値 | 前日比 | 騰落率 | 出来高 |
|---|---|---|---|---|---|---|---|
| 2024/09/06 | 1,581 | 1,581 | 1,556 | 1,560 | -21 | -1.3% | 88,900 |
| 2024/09/05 | 1,588 | 1,597 | 1,567 | 1,581 | -6 | -0.4% | 90,200 |
| 2024/09/04 | 1,601 | 1,616 | 1,584 | 1,587 | -34 | -2.1% | 117,000 |
| 2024/09/03 | 1,614 | 1,626 | 1,614 | 1,621 | +7 | +0.4% | 31,300 |
| 2024/09/02 | 1,625 | 1,630 | 1,606 | 1,614 | -10 | -0.6% | 78,000 |
| 2024/08/30 | 1,615 | 1,628 | 1,615 | 1,624 | +9 | +0.6% | 53,300 |
| 2024/08/29 | 1,623 | 1,630 | 1,613 | 1,615 | -19 | -1.2% | 35,700 |
| 2024/08/28 | 1,621 | 1,634 | 1,619 | 1,634 | +1 | +0.1% | 25,900 |
| 2024/08/27 | 1,632 | 1,637 | 1,622 | 1,633 | +15 | +0.9% | 33,000 |
| 2024/08/26 | 1,618 | 1,623 | 1,610 | 1,618 | -14 | -0.9% | 48,500 |
| 2024/08/23 | 1,628 | 1,638 | 1,625 | 1,632 | +11 | +0.7% | 52,500 |
| 2024/08/22 | 1,635 | 1,636 | 1,617 | 1,621 | -14 | -0.9% | 44,500 |
| 2024/08/21 | 1,621 | 1,637 | 1,620 | 1,635 | +4 | +0.2% | 43,600 |
| 2024/08/20 | 1,615 | 1,638 | 1,615 | 1,631 | +18 | +1.1% | 51,600 |
| 2024/08/19 | 1,620 | 1,628 | 1,608 | 1,613 | -17 | -1% | 48,100 |
| 2024/08/16 | 1,625 | 1,632 | 1,608 | 1,630 | +25 | +1.6% | 57,500 |
| 2024/08/15 | 1,618 | 1,618 | 1,601 | 1,605 | -5 | -0.3% | 46,700 |
| 2024/08/14 | 1,606 | 1,612 | 1,594 | 1,610 | +4 | +0.2% | 67,200 |
| 2024/08/13 | 1,597 | 1,612 | 1,597 | 1,606 | +9 | +0.6% | 53,300 |
| 2024/08/09 | 1,611 | 1,617 | 1,571 | 1,597 | +23 | +1.5% | 94,000 |
| 2024/08/08 | 1,551 | 1,606 | 1,551 | 1,574 | +1 | +0.1% | 82,300 |
| 2024/08/07 | 1,551 | 1,611 | 1,543 | 1,573 | +11 | +0.7% | 155,600 |
| 2024/08/06 | 1,552 | 1,593 | 1,530 | 1,562 | +63 | +4.2% | 160,000 |
| 2024/08/05 | 1,634 | 1,634 | 1,499 | 1,499 | -157 | -9.5% | 211,300 |
| 2024/08/02 | 1,686 | 1,686 | 1,648 | 1,656 | -30 | -1.8% | 163,400 |
| 2024/08/01 | 1,703 | 1,751 | 1,678 | 1,686 | -35 | -2% | 186,900 |
| 2024/07/31 | 1,694 | 1,726 | 1,694 | 1,721 | +13 | +0.8% | 91,800 |
| 2024/07/30 | 1,714 | 1,718 | 1,703 | 1,708 | -9 | -0.5% | 84,900 |
| 2024/07/29 | 1,711 | 1,719 | 1,706 | 1,717 | +16 | +0.9% | 76,200 |
| 2024/07/26 | 1,701 | 1,710 | 1,696 | 1,701 | -6 | -0.4% | 80,000 |
| 2024/07/25 | 1,707 | 1,715 | 1,699 | 1,707 | -4 | -0.2% | 151,800 |
| 2024/07/24 | 1,714 | 1,721 | 1,705 | 1,711 | -10 | -0.6% | 92,100 |
| 2024/07/23 | 1,705 | 1,721 | 1,705 | 1,721 | +16 | +0.9% | 74,500 |
| 2024/07/22 | 1,726 | 1,731 | 1,705 | 1,705 | -24 | -1.4% | 98,000 |
| 2024/07/19 | 1,721 | 1,729 | 1,709 | 1,729 | ±0 | ±0% | 83,300 |
| 2024/07/18 | 1,710 | 1,734 | 1,710 | 1,729 | +10 | +0.6% | 84,700 |
| 2024/07/17 | 1,715 | 1,719 | 1,705 | 1,719 | +14 | +0.8% | 61,900 |
| 2024/07/16 | 1,716 | 1,723 | 1,705 | 1,705 | -23 | -1.3% | 86,300 |
| 2024/07/12 | 1,707 | 1,728 | 1,707 | 1,728 | +14 | +0.8% | 103,900 |
| 2024/07/11 | 1,704 | 1,718 | 1,704 | 1,714 | +14 | +0.8% | 99,500 |
| 2024/07/10 | 1,700 | 1,702 | 1,688 | 1,700 | ±0 | ±0% | 79,500 |
| 2024/07/09 | 1,688 | 1,706 | 1,685 | 1,700 | +17 | +1% | 113,500 |
| 2024/07/08 | 1,699 | 1,702 | 1,677 | 1,683 | ±0 | ±0% | 157,200 |
| 2024/07/05 | 1,695 | 1,698 | 1,678 | 1,683 | -17 | -1% | 90,900 |
| 2024/07/04 | 1,695 | 1,700 | 1,694 | 1,700 | +9 | +0.5% | 62,900 |
| 2024/07/03 | 1,691 | 1,699 | 1,688 | 1,691 | -3 | -0.2% | 69,300 |
| 2024/07/02 | 1,698 | 1,704 | 1,691 | 1,694 | -3 | -0.2% | 77,900 |
| 2024/07/01 | 1,706 | 1,706 | 1,692 | 1,697 | -5 | -0.3% | 92,500 |
| 2024/06/28 | 1,704 | 1,706 | 1,692 | 1,702 | ±0 | ±0% | 70,800 |
| 2024/06/27 | 1,710 | 1,710 | 1,695 | 1,702 | -12 | -0.7% | 75,500 |
51～
100
件表示中 / 3585件
類似銘柄と比較する
現在ご覧いただいている「杏林製薬」と類似性の高い銘柄をピックアップ。投資家が注目しているデータで比較できるようになっています。銘柄選びの参考情報としてご活用ください。
| 銘柄名 | 最低購入代金 | 売上高 成長率 |
経常 増益率 |
配当 利回り |
PER | PBR | 直近のチャート | 特色 |
|---|---|---|---|---|---|---|---|---|
| 杏林製薬 | 149,100円 | +3.2% | +4.5% | 3.49% | 17.13倍 | 0.66倍 |
|
医薬中堅。柱のぜんそく薬、呼吸器アレルギー薬は下期に比重。消化器領域育成。後発品も |
| ゼリア新薬 | 222,100円 | +13.6% | +29.2% | 2.07% | 11.52倍 | 1.11倍 |
|
製薬中堅。医療用は消化器系中心。滋養強壮剤「ヘパリーゼ」も柱。スイス企業買収で海外展開 |
| ネクセラファーマ | 113,700円 | +197.7% | - | 0.00% | 46.47倍 | 1.48倍 |
|
創薬ベンチャー老舗。買収で成長。英国の創薬事業に日本が柱の後期治験・製造販売事業加わる |
| ＪＣＲファーマ | 69,600円 | -3.7% | -36.7% | 2.87% | 22.92倍 | 1.50倍 |
|
ヒト成長ホルモン製剤が主力、バイオ後続品も成長。希少疾病のバイオ新薬開発にも取り組む |
| 栄研化 | 210,100円 | +0.4% | -8.4% | 2.52% | 27.77倍 | 1.58倍 |
|
臨床検査薬大手。便潜血検査試薬（ＦＩＴ）はシェア７割。尿検査（ウロ）、遺伝子検査も育成 |
市場注目の銘柄
チャート関連のコラム
